DUBLIN–(BUSINESS WIRE)–The “Parkinson’s Disease Treatment: Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
Global Parkinson’s Disease Treatment Market to Reach $6.7 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Parkinson’s Disease Treatment estimated at US$4.6 Billion in the year 2020, is projected to reach a revised size of US$6.7 Billion by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027.
Levodopa / Carbidopa, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$2.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Dopamine Receptor Agonists segment is readjusted to a revised 4.7% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 8.3% CAGR
The Parkinson’s Disease Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 8.4% over the analysis period 2020 to 2027.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.8% and 4.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$882.1 Million by the year 2027.
MAO-Inhibitors Segment to Record 5.6% CAGR
In the global MAO-Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 5.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$594.3 Million in the year 2020 will reach a projected size of US$841.6 Million by the close of the analysis period.
China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 6.8% CAGR through the analysis period.
What’s New for 2022?
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies – Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Parkinson’s Disease Treatment – Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS (Total 42 Featured)
- AbbVie
- Acadia
- Boehringer Ingelheim
- Dr. Reddy’s
- GSK
- Impax
- Lundbeck
- Merck
- Novartis
- Sun Pharma
- Teva
- UCB
- US WorldMeds
- Valeant Pharmaceuticals
- Wockhardt
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. REGIONAL MARKET ANALYSIS
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/6xohn2
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
